CDKN2A and meningioma: Additionally, WHO grading criteria for meningioma were revised in 2016 (adding brain invasion as a criterion for grade 2)57 and again in 2021 (incorporating molecular markers such as CDKN2A/B deletion and TERT promoter mutation),4 which may have introduced differences in diagnostic classification or management over time.